Literature DB >> 31430418

Anti-CD40 antibody 2C10 binds to a conformational epitope at the CD40-CD154 interface that is conserved among primate species.

Anthony J Michaels1, Matteo Stoppato1, Walter J Flores1, Keith A Reimann1, Kathleen D Engelman1.   

Abstract

The antagonistic anti-CD40 antibody, 2C10, and its recombinant primate derivative, 2C10R4, are potent immunosuppressive antibodies whose utility in allo- and xenotransplantation have been demonstrated in nonhuman primate studies. In this study, we defined the 2C10 binding epitope and found only slight differences in affinity of 2C10 for CD40 derived from four primate species. Staining of truncation mutants mapped the 2C10 binding epitope to the N-terminal portion of CD40. Alanine scanning mutagenesis of the first 60 residues in the CD40 ectodomain highlighted key amino acids important for binding of 2C10 and for binding of the noncross-blocking anti-CD40 antibodies 3A8 and 5D12. All four 2C10-binding residues defined by mutagenesis clustered near the membrane-distal tip of CD40 and partially overlap the CD154 binding surface. In contrast, the overlapping 3A8 and 5D12 epitopes map to an opposing surface away from the CD154 binding domain. This biochemical characterization of 2C10 confirms the validity of nonhuman primate studies in the translation of this therapeutic antibody and provides insight its mechanism of action.
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  B cell biology; animal models: nonhuman primate; antibody biology; antigen biology; basic (laboratory) research/science; costimulation; immunobiology; immunosuppression/immune modulation; translational research/science

Year:  2019        PMID: 31430418      PMCID: PMC6940519          DOI: 10.1111/ajt.15574

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  29 in total

1.  Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins.

Authors:  M de Boer; L Conroy; H Y Min; J Kwekkeboom
Journal:  J Immunol Methods       Date:  1992-07-31       Impact factor: 2.303

Review 2.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

3.  Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival.

Authors:  Andrew B Adams; Nozomu Shirasugi; Thomas R Jones; Megan M Durham; Elizabeth A Strobert; Shannon Cowan; Phyllis Rees; Rose Hendrix; Karen Price; Norma S Kenyon; David Hagerty; Robert Townsend; Dianne Hollenbaugh; Thomas C Pearson; Christian P Larsen
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

Review 4.  Modularity in the TNF-receptor family.

Authors:  J H Naismith; S R Sprang
Journal:  Trends Biochem Sci       Date:  1998-02       Impact factor: 13.807

5.  Evaluation of calibration-free concentration analysis provided by Biacore™ systems.

Authors:  Ewa Pol; Håkan Roos; Francis Markey; Fredrik Elwinger; Alan Shaw; Robert Karlsson
Journal:  Anal Biochem       Date:  2016-07-09       Impact factor: 3.365

6.  Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates.

Authors:  I R Badell; P W Thompson; A P Turner; M C Russell; J G Avila; J A Cano; J M Robertson; F V Leopardi; E A Strobert; N N Iwakoshi; K A Reimann; M L Ford; A D Kirk; C P Larsen
Journal:  Am J Transplant       Date:  2011-09-15       Impact factor: 8.086

7.  Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40.

Authors:  Katherine C Bankert; Kyp L Oxley; Sonja M Smith; John P Graham; Mark de Boer; Marielle Thewissen; Peter J Simons; Gail A Bishop
Journal:  J Immunol       Date:  2015-03-20       Impact factor: 5.422

Review 8.  Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.

Authors:  David F Pinelli; Mandy L Ford
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

9.  A novel monoclonal antibody to CD40 prolongs islet allograft survival.

Authors:  M Lowe; I R Badell; P Thompson; B Martin; F Leopardi; E Strobert; A A Price; H S Abdulkerim; R Wang; N N Iwakoshi; A B Adams; A D Kirk; C P Larsen; K A Reimann
Journal:  Am J Transplant       Date:  2012-05-08       Impact factor: 8.086

10.  Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.

Authors:  Sudha Visvanathan; Stefan Daniluk; Rafał Ptaszyński; Ulf Müller-Ladner; Meera Ramanujam; Bernd Rosenstock; Anastasia G Eleftheraki; Richard Vinisko; Alena Petříková; Herbert Kellner; Eva Dokoupilova; Brygida Kwiatkowska; Rieke Alten; Christian Schwabe; Patrick Baum; David Joseph; Jay S Fine; Steven J Padula; Jürgen Steffgen
Journal:  Ann Rheum Dis       Date:  2019-03-22       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.